Alteogen Inc. · KRX:196170
Alteogen — J.P. Morgan Healthcare Conference 2026
18 slides from Alteogen's conference presentation, Jan 15, 2026
Slide 1: J.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference Tae-Yon Chun, Chief Executive Officer January 15, 2026 @ ALTEOGEN
Slide 2: Disclaimer
Disclaimer This company presentation contains proprietary and confidential information of Alteogen Inc. and is provided solely for the purpose of providing a general outline of Alteogen Inc.'s technology & business scope. This presentation shall not be reproduced, distributed, or disclosed, in whole
Slide 3: Company Overview
=< Company Overview Alteogen is dedicated to developing next-generation biologics to improve quality of life. Alteogen Inc. © Corporate Information Established CEO Headquarters Stock code Subsidiary Website May 13th, 2008 Tae-Yon Chun, Ph.D. Daejeon, South Korea KOSDAQ 196170 Alteogen Biologics - Ey
Slide 4: Alteogen's Core Technology Platforms
=== Alteogen’s Core Technology Platforms We pursue breakthrough R&D beyond conventional biologics through its core platform technologies Va Hybrozyme™ Novel Human Hyaluronidase - Enabling large volume subcutaneous delivery - Competitive patent portfolio (secured substance, co-formulation, and proces
Slide 5: Robust Pipeline
=== Robust Pipeline Alteogen is expanding its robust pipeline, including ALT-B4 for subcutaneous formulation conversion @ALTEOGEN @ Approved In Development Tergase® eH SE°(ALT-L2) Hybrozyme™ Weekly hGH* Standalone ALT-B4 Herceptin® biosimilar ALT-B4 ALT-P1 recombinant human hyaluronidase MFDS (South
Slide 6: ALT-B4: A Novel Hyaluronidase Enabling Subcutaneous Delivery via Hybrozyme
ALT-B4: A Novel Hyaluronidase Enabling Subcutaneous Delivery via Hybrozyme™ HYAL1 - 3D structure of hyaluronidase-1 Alteogen’s proprietary . . identified recombinant human © Differentiation from rHuPH20 hyaluronidase . Enhanced protein stability A LT B 4 with higher tolerance to = thermal stress (IN
Slide 7: Subcutaneous Injections Benefit Patients, Healthcare Providers, and Pharmaceutical Companies
=== Subcutaneous Injections Benefit Patients, Healthcare Providers, and Pharmaceutical Companies SC Formulation ( High Demand for Patients - Pharma - Healthcare Providers Patients Improved patient convenience and quality of life Reduced time in-chair and in the treatment room No IV infusion related
Slide 8: Six Global Pharma Licensing Agreements for SC Formulation Conversion
=== Six Global Pharma Licensing Agreements for SC Formulation Conversion Licensing Agreements for Subcutaneous (SC) Formulation Conversion * Nov. 29 ° Jan.7 _ Non-exclusive license Exclusive license | agreement agreement _ Top 10 Global Intas i Pharmaceutical Company | for multiple products for two
Slide 9: Expanding ALT-B4 Applicability Beyond Traditional Monoclonal Antibodies
Expanding ALT-B4 Applicability Beyond Traditional Monoclonal Antibodies Bispecific mAb \\ | * ALTEOGEN Multiple collaboration opportunities with same-target mAbs and different modalities ALT-B4 Single Target . or mAb Expansion of the use of (Antibody Drug Hybrozyme technology Conjugate) RNA Investor
Slide 10: Tergase Offers Higher Purity and Safety than Conventional Animal-Derived Hyaluronidases
Tergase® Offers Higher Purity and Safety than Conventional Animal-Derived Hyaluronidases Tergase® TERGASE Gs - Standalone hyaluronidase product administered subcutaneously to reduce : = 1 il pain or swelling after dermal filler injection or surgeries Recombinant human hyaluronidase of higher purity
Slide 11: Continue to Grow Through Collaboration Revenue and Innovative In-House Drug Development
=== Continue to Grow Through Collaboration Revenue and Innovative In-House Drug Development © Hybrid Business Model @ Revenue & Profit Growth* (2022- Q3 2025) (Unit: KRW in millions) 181 140,000 ¥: 120,000 vonnoa 96,523 102,854 Platform Internal . . 80,000 Licensing Development a 60,000 Generate rev
Slide 12: AHV (cm)
12 AHV (cm) 8 4 0 ALT-P1 0.6 mpk ALT-P1 0.8 mpk Genotropin
Slide 13: Ultra-Long-Acting Platform Fusion Technology
=== Ultra-Long-Acting Platform Fusion Technology A once-monthly formulation development rrent Obesity Treatmen' idscapi Daily Injections > Weekly Injections (e.g.) Saxenda (Q1D), Wegovy (Q1W), Zepbound (Q1W) Daily Oral Pills In development by pharmaceutical There is still an unmet medical need for l
Slide 14: Plans for Manufacturing Facilities
Plans for Manufacturing Facilities Aiming to establish manufacturing facilities for biopharmaceuticals, including ALT-B4, Tergase®, and Eyluxvi® Targets ALO-2 (009 | iil OareaS Ler Securing strategic flexibility {ty drug substance (DS) and drug in manufacturing products (DP) Engagement with domestic
Slide 15: Sustained Growth Driven by Multiple SC Products Under License Agreements
=== Sustained Growth Driven by Multiple SC Products Under License Agreements, Starting with the First SC Product Launch Utilizing Hybrozyme™ in 2025 Commercialization of three products - Tergase and two products by partners Y<TERGASE" Beith ee KEYTRUDA Qlex™ setkurd yaaa alee 2024 2025 @ALTEOGEN Com
Slide 16: Technologies for a Better Life
jes for a Better Life ——— Pi =
Slide 17: Financial Information
=—= Financial Information © Condensed Consolidated Statements of Income (KRW in millions) Collaboration revenue Product sales Total revenue Cost of sales Gross profit SG&A expense Operating income Other income (expense) Finance income (expense) Income before income tax expense Net income (loss) 9mYT
Slide 18: Alteogen
ALTEOQGEN www.alteogen.com